CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
CELZNasdaq
$0.88
↑ +2.2%Jul 17 close · end-of-day
Price
1Y↓ -64.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$3.3M
Enterprise Value
$3.3M
P/E
—
P/S
1084.6
P/B
0.5
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$3,000.00
Net Income (TTM)
-$5.8M
Free Cash Flow (TTM)
—
Gross Margin
66.9%
Operating Margin
-198049.6%
Net Margin
-192066.3%
ROE
-94.3%
ROIC
-76.8%
Debt / Equity
—
Net Cash
—
Return 1Y
-66.5%
Company profile
Creative Medical Technology Holdings, Inc. focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness.
- CEO
- Timothy Warbington
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 5
- Headquarters
- Arizona
Earnings
CELZ Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$0.00↓ -100.0%
Diluted EPS-$0.38↓ -54.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $164,500.00 | $87,754.00 | $88,600.00 | $9,000.00 | $11,000.00 | $6,000.00 |
| Gross profit | $113,904.00 | $39,805.00 | $60,109.00 | $5,400.00 | $6,600.00 | $3,806.00 |
| Operating income | -$1.1M | -$3.1M | -$10.2M | -$5.6M | -$5.7M | -$6.1M |
| Net income | -$36.3M | $19.2M | -$10.1M | -$5.3M | -$5.5M | -$6.0M |
| Diluted EPS | -$62.69 | $5.61 | -$0.93 | -$3.76 | -$3.71 | -$2.52 |
| Operating cash flow | -$434,556.00 | -$2.2M | -$7.8M | -$8.0M | -$5.3M | -$5.9M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | 69.2% | 45.4% | 67.8% | 60.0% | 60.0% | 63.4% |
| Operating margin | -677.7% | -3562.2% | -11562.5% | -62445.9% | -52216.9% | -102380.2% |
| Net margin | -22082.2% | 21892.8% | -11449.3% | -58739.7% | -49940.7% | -99916.8% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8,000.00 | $0.00 | $3,000.00 | $3,000.00 | $0.00 | $0.00 | $3,000.00 | $0.00 |
| Gross profit | $4,800.00 | $0.00 | $1,800.00 | $1,800.00 | $0.00 | $0.00 | $2,006.00 | $0.00 |
| Operating income | -$1.6M | -$1.1M | -$1.9M | -$1.7M | -$1.3M | -$1.3M | -$1.9M | -$1.5M |
| Net income | -$1.6M | -$1.0M | -$1.9M | -$1.6M | -$1.2M | -$1.2M | -$1.9M | -$1.4M |
| Diluted EPS | -$1.11 | -$0.75 | -$2.58 | -$0.83 | -$0.48 | -$0.48 | -$0.73 | -$0.38 |
| Operating cash flow | -$1.5M | -$985,588.00 | -$1.9M | -$1.6M | -$1.2M | -$1.2M | -$1.9M | -$1.3M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | 60.0% | — | 60.0% | 60.0% | — | — | 66.9% | — |
| Operating margin | -20316.3% | — | -62857.8% | -55349.3% | — | — | -64859.4% | — |
| Net margin | -19471.6% | — | -61802.5% | -54603.2% | — | — | -62922.5% | — |
Company news
Jun 16, 2026
- 34d agoCreative Medical Technology opens nationwide burn-pit data registryproactiveinvestors.com
- 34d agoCreative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazardsfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.